Barely Significant
← all phrases

“narrowly missed statistical significance”

228 sentences · 228 papers · 276 search hits before verification

In the literature

5 In terms of clinical outcomes, two moderately sized randomized trials published prior to HEART‐FID (Ferric Carboxymaltose in Heart Failure with Iron Deficiency) demonstrated a reduction in HF hospitalizations and cardiovascular deaths in both hospitalized and stable patients which narrowly missed statistical significance. 6 , 7 The HEART‐FID trial further substantiated these results; thus, consideration of iron replacement in eligible patients with HF and ID is warranted. 8 , 9 The efficacy and safety of intravenous ferric carboxymaltose (FCM) has previously been demonstrated in multiple disease states (e.g. chronic kidney disease [CKD], inflammatory bowel disease, heavy uterine bleeding, postpartum period) including HF. 7 , 10 , 11 Prior studies with FCM have shown transient, asymptomatic hypophosphataemia.
44 , 45 This maybe the reason behind the fact that improvement in pCR by 20% in the case of the Neo-ALLTO trial, narrowly missed statistical significance in the ALLTO trial (HR 0.84, 97.5 % CI 0.70-1.02). 46 , 47 Selected ongoing Cb NACT studies in TNBC There are several studies evaluating various schedules and combinations of Cb in the NACT of TNBC ( Table 2 ).
This exploratory pilot study also reported a decrease in baseline/interictal saliva CGRP levels for participants receiving BoNT, although this difference was only observed after the third month and narrowly missed statistical significance when compared to placebo-control group.
Taken together, while these results indicate a direction of improvement, the fact that the primary pooled effect narrowly missed statistical significance, combined with high heterogeneity, suggests that the evidence for a general beneficial effect on PTSD symptoms remains inconclusive in the overall analysis.
The worsening of renal function was 1.4% and 2.7% respectively (hazard ratio, 0.50; 95% CI, 0.33 to 0.77).The results of the Phase III PARAGON-HF study showed a 13% relative reduction in the primary composite endpoint of cardiovascular death and total (first and recurrent) heart failure hospitalizations, but narrowly missed statistical significance. 98 Sodium-glucose co-transporter-2 inhibitors (SGLT-2is) have significantly improved HF outcomes in patients with diabetes mellitus type 2 (T2D) and may represent a new therapeutic alternative for patients with T2D at risk for or with HF.